GLOW

Name: GLOW
SKU: 1213
Availability: InStock

$179.00

Size

Clear

In stock
COA-verified
≥99% purity.
USA manufactured.
In stock
COA-verified
≥99% purity.
USA manufactured.
COA-verified
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.

WHAT IS GLOW?

GLOW is a multi-component peptide research blend containing three distinct compounds: GHK-Cu, a copper-binding tripeptide; BPC-157, a synthetic pentadecapeptide; and TB-500, a synthetic fragment of thymosin β4. The combination is investigated in research models for potential synergistic activity across overlapping tissue-repair and regenerative pathways.
BioRhex supplies the GLOW blend as a research formulation manufactured in a GMP-compliant US facility, tested to ≥ 99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.

The GLOW blend combines three peptides investigated for their interactions with tissue-remodeling and regenerative signaling systems. In vitro and preclinical models examine how the blend may influence:

Collagen synthesis and extracellular-matrix remodeling (GHK-Cu)
Angiogenesis and VEGF-associated signaling (BPC-157)
Actin-dependent cellular migration (TB-500)
Fibroblast proliferation and gene-expression modulation
Combined multi-pathway tissue-repair dynamics

The GLOW blend was formulated as a research combination of three individually characterized peptides — GHK-Cu, first isolated from human plasma in 1973; BPC-157, a synthetic pentadecapeptide derived from a gastric-protein sequence; and TB-500, a synthetic fragment of the naturally occurring protein thymosin β4.
In vitro and preclinical findings related to each component’s role in tissue repair expanded interest in combined formulations as research tools for studying multi-pathway regenerative processes.
The GLOW blend continues to be investigated within tissue-repair and regenerative pathway research in controlled laboratory environments.

Reserch-grade coenzyme compound visualization.

COMPOUND

GHK-Cu + BPC-157 + TB-500

TYPE

Three-peptide research blend

MOLECULAR FORMULA

50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500

MOLECULAR WEIGHT

70 mg lyophilized

PURITY

≥99%

ANALYSIS

HPLC Verified

STORAGE

Store at -20°C. Protect from light and moisture.

CLASSIFICATION

Reserch Use Only

Research Findings

Published and preclinical research on GLOW covers several areas of scientific investigation, including:

Tissue repair research: Studies examine the blend’s components in wound-healing and reepithelialization models.
Angiogenesis research: Studies examine BPC-157 and TB-500 interactions with VEGF-associated blood-vessel formation in experimental systems.
Extracellular matrix research: Studies examine GHK-Cu’s interactions with collagen synthesis and matrix remodeling.
Cellular migration research: Studies examine TB-500’s actin-sequestering properties and their role in cell-motility models.

All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.

References

1. Pickart L, Margolina A (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987. https://doi.org/10.3390/ijms19071987

2. Pickart L, Vasquez-Soltero JM, Margolina A (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015, 648108. https://doi.org/10.1155/2015/648108

3. Seiwerth S, Milavić M, Vukojević J, et al. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533

4. Malinda KM, Sidhu GS, Mani H, et al. (1999). Thymosin β4 accelerates wound healing. Journal of Investigative Dermatology, 113(3), 364–368. https://doi.org/10.1046/j.1523-1747.1999.00708.x

FAQ

What type of research is the GLOW used for?

GLOW is used in laboratory research settings. All supplied compounds are intended strictly for in vitro and preclinical research purposes. Use is limited to controlled scientific environments.

Where is BioRhex’s the GLOW manufactured?

All BioRhex compounds, including the GLOW, are manufactured in a GMP-compliant facility located in the United States.

What testing does BioRhex conduct on the GLOW?

Every batch of the GLOW undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥ 99% threshold.

Is the GLOW approved for human use?

No. GLOW is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.

Who should handle this compound?

Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.

All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. the GLOW is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.